Patents by Inventor Baris Ugar Agar

Baris Ugar Agar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis
    Patent number: 9132219
    Abstract: A method of predicting serum potassium concentrations in a patient during hemodialysis includes measuring serum potassium concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a potassium mobilization clearance and a pre-dialysis distribution volume of potassium for the patient. Serum potassium concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated potassium mobilization clearance and pre-dialysis distribution volume of potassium of the patient.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: September 15, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alp Akonur, John Kenneth Leypoldt, Yin-Cheng Lo, Baris Ugar Agar
  • Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
    Patent number: 8845570
    Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: September 30, 2014
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Alp Akonur, John Kenneth Leypoldt, Ying-Cheng Lo, Baris Ugar Agar
  • THERAPY PREDICTION AND OPTIMIZATION OF SERUM POTASSIUM FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS
    Publication number: 20140042092
    Abstract: A method of predicting serum potassium concentrations in a patient during hemodialysis includes measuring serum potassium concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a potassium mobilization clearance and a pre-dialysis distribution volume of potassium for the patient. Serum potassium concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated potassium mobilization clearance and pre-dialysis distribution volume of potassium of the patient.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 13, 2014
    Applicants: Baxter International Inc.
    Inventors: Alp Akonur, John Kenneth Leypoldt, Yin-Cheng Lo, Baris Ugar Agar
  • THERAPY PREDICTION AND OPTIMIZATION FOR RENAL FAILURE BLOOD THERAPY, ESPECIALLY HOME HEMODIALYSIS
    Publication number: 20110257891
    Abstract: A method of predicting serum phosphorus concentrations in a patient during hemodialysis includes measuring serum phosphorus concentrations of the patient over a hemodialysis treatment session time and an ultrafiltration rate calculated by a difference between pre- and post-dialytic body weight of the patient during an initial hemodialysis treatment session divided by a total treatment time of the treatment session and estimating a phosphorous mobilization clearance and a pre-dialysis distribution volume of phosphorus for the patient. Serum phosphorus concentrations of the patient can then be predicted at any time during any hemodialysis treatment session with the estimated phosphorous mobilization clearance and pre-dialysis distribution volume of phosphorus of the patient.
    Type: Application
    Filed: April 15, 2011
    Publication date: October 20, 2011
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Alp Akonur, John Kenneth Leypoldt, Ying-Cheng Lo, Baris Ugar Agar